Skip to main content
Premium Trial:

Request an Annual Quote

CHI Says Toxicogenomics Can Quash Drug-Development Flops

NEW YORK, April 16 - Toxicogenomics is the key to eliminating drug-development failures, according to a report from the Cambridge Healthtech Institute.

 

The forthcoming study heralds toxicogenomics as a crucial part of the future of drug development. This technology, according to the report, promises faster, more accurate, and more efficient screening and elimination of potential compounds, and substantially reduced R&D costs.

 

It describes public and private efforts to advance toxicogenomic studies, including both environmental and pharmaceutical applications of this technology. The report also includes profiles of several dozen toxicogenomic companies and an analysis of their deals.

 

Cambridge Healthtech generates reports and hosts conferences about the application of genomic technologies in industry.